Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Siu Hin Wan; Isabel Torres-Courchoud; Paul M. McKie; Joshua P. Slusser; Margaret M. Redfield; John C. Burnett; David O. Hodge; Horng H. Chen

doi:10.1016/j.jacbts.2019.08.008

Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Siu Hin Wan, Isabel Torres-Courchoud, Paul M. McKie, Joshua P. Slusser, Margaret M. Redfield, John C. Burnett, David O. Hodge, Horng H. Chen

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow.

Original language	English (US)
Pages (from-to)	962-972
Number of pages	11
Journal	JACC: Basic to Translational Science
Volume	4
Issue number	8
DOIs	https://doi.org/10.1016/j.jacbts.2019.08.008
State	Published - Dec 2019
Externally published	Yes

Keywords

B-type natriuretic peptide
cardiorenal
heart failure
nesiritide
phosphodiesterase inhibition
systolic dysfunction

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacbts.2019.08.008

Cite this

@article{96a7f4df6b5447e0830eb57967b94f77,

title = "Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP",

abstract = "Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow.",

keywords = "B-type natriuretic peptide, cardiorenal, heart failure, nesiritide, phosphodiesterase inhibition, systolic dysfunction",

author = "Wan, {Siu Hin} and Isabel Torres-Courchoud and McKie, {Paul M.} and Slusser, {Joshua P.} and Redfield, {Margaret M.} and Burnett, {John C.} and Hodge, {David O.} and Chen, {Horng H.}",

note = "Funding Information: This research was supported by grants from the National Institutes of Health (PO1 HL 76611, R01 HL 84155, HL136440) and NIH/NCRR Center for Translational Science Activities (grant number UL1 RR024150). Drs. Wan and Torres-Courchoud contributed equally to this work and are joint first authors. Drs. Chen and Burnett hold patents and licensed designer natriuretic peptides; and are co-founders of Zumbro Discovery. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2019",

month = dec,

doi = "10.1016/j.jacbts.2019.08.008",

language = "English (US)",

volume = "4",

pages = "962--972",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

AU - Wan, Siu Hin

AU - Torres-Courchoud, Isabel

AU - McKie, Paul M.

AU - Slusser, Joshua P.

AU - Redfield, Margaret M.

AU - Burnett, John C.

AU - Hodge, David O.

AU - Chen, Horng H.

N1 - Funding Information: This research was supported by grants from the National Institutes of Health (PO1 HL 76611, R01 HL 84155, HL136440) and NIH/NCRR Center for Translational Science Activities (grant number UL1 RR024150). Drs. Wan and Torres-Courchoud contributed equally to this work and are joint first authors. Drs. Chen and Burnett hold patents and licensed designer natriuretic peptides; and are co-founders of Zumbro Discovery. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2019 The Authors

PY - 2019/12

Y1 - 2019/12

N2 - Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow.

AB - Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow.

KW - B-type natriuretic peptide

KW - cardiorenal

KW - heart failure

KW - nesiritide

KW - phosphodiesterase inhibition

KW - systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85076669204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076669204&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2019.08.008

DO - 10.1016/j.jacbts.2019.08.008

M3 - Article

C2 - 31909303

AN - SCOPUS:85076669204

SN - 2452-302X

VL - 4

SP - 962

EP - 972

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 8

ER -

Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this